A Study of CD19 UCAR-T Cells in Subjects With Autoimmune Diseases

Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Study ID
NCT07212322
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Not accepted

Interventions

  • CD19 UCAR-T cells — DRUG
    CD19 UCAR-T cells treatment

Study Details

The purpose of this study is to assess the safety and efficacy of CD19 UCAR-T cell therapy in Subjects with autoimmune diseases.

Key Dates

Start date
Jan 30, 2026
Status verified
Sep 2025
Primary completion
May 20, 2027
Completion
Jul 20, 2027

Study Design

Enrollment
24 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: treatment

Primary Outcome Measure

Dose Limiting Toxicity [ Time Frame: Time Frame: 0~28 day after treatment ]

Central Contacts

Related Studies